VERV - Intellia and gene editors lead weekly healthcare gainers; CEL-SCI and Citius trail

Matteo Colombo/DigitalVision via Getty Images S&P 500 Health Care Sector Index rose ~2.0% over the week to outpace the ~1.7% gain in the S&P 500 as gene editing companies rallied after Intellia (NTLA) and Regeneron (REGN) showed promise in the CRISPR technology with first-ever clinical data supporting the in-vivo gene editing. Intellia led weekly gainers in the industry with a ~84.3% rise over the past five days while other gene-editing leveraged tickers such as Beam Therapeutics (BEAM) and recently IPO’ed Verve Therapeutics (VERV) were not far behind, with each rising more than a third. Seeking Alpha contributor Dan Strack details why NTLA-2001, for which the company showcased positive Phase 1 interim data last Saturday in Transthyretin amyloidosis ((ATTR)), “is a proving ground for Intellia.” Meanwhile, COVID-19 vaccine developers, Novavax (NVAX), and Moderna (MRNA) were among the five biggest weekly gainers in the category of large-cap biotech players, with a rise of ~14.5% and ~6.5%, respectively, as fears over the Delta variant

For further details see:

Intellia and gene editors lead weekly healthcare gainers; CEL-SCI and Citius trail